

ORDERING OFFICE, ALSO FAX:

- Most recent labs
- Supporting clinicals / Recent H&P
- Insurance card, front and back

Certolizumab (Cimzia)

Provider Order Form



Date:	Patient Name:	DOB:
ICD-10 code (required):		
ICD-10 description:		
<input type="checkbox"/> NKDA Allergies:		Weight lbs/kg:
Ordering Provider:	Provider NPI:	
Referring Practice Name:	Phone:	Fax:
Practice Address:	City:	State: Zip Code:
NURSING		
<input checked="" type="checkbox"/> Provide nursing care per IVX Standard Nursing Procedures, including reaction management and post-infusion observation		
<input checked="" type="checkbox"/> TB status and date (Please provide results) _____		
<input checked="" type="checkbox"/> Hepatitis B status and date (Please provide results) _____		
PRE-MEDICATION ORDERS (ADMINISTER 30 MINUTES PRIOR TO PROCEDURE)		
<input type="checkbox"/> acetaminophen (Tylenol) <input type="checkbox"/> 500mg / <input type="checkbox"/> 650mg / <input type="checkbox"/> 1000mg PO		
<input type="checkbox"/> cetirizine (Zyrtec) 10mg PO		
<input type="checkbox"/> loratadine (Claritin) 10mg PO		
<input type="checkbox"/> diphenhydramine (Benadryl) <input type="checkbox"/> 25mg / <input type="checkbox"/> 50mg <input type="checkbox"/> PO / <input type="checkbox"/> IV		
<input type="checkbox"/> methylprednisolone (Solu-Medrol) <input type="checkbox"/> 40mg / <input type="checkbox"/> 125mg IV		
<input type="checkbox"/> Other:		
Dose:	Route:	Frequency:
MEDICATION THERAPY		
<input checked="" type="checkbox"/> certolizumab pegol (Cimzia) subcutaneous injection		
<input type="checkbox"/> Induction		
▪ Dose: <input type="checkbox"/> 400mg / <input type="checkbox"/> _____ mg at Week 0, 2, 4, and then with maintenance dosing below		
▪ Give each 200mg injection separately		
<input type="checkbox"/> Maintenance		
▪ Dose: <input type="checkbox"/> 200mg / <input type="checkbox"/> 400mg		
▪ Frequency: <input type="checkbox"/> every 2 weeks / <input type="checkbox"/> every 4 weeks / <input type="checkbox"/> other: _____		
<input type="checkbox"/> Patient is required to stay for 30-minute observation post injection		
<input type="checkbox"/> Patient is NOT required to stay for observation time		
<input type="checkbox"/> Refills: <input type="checkbox"/> Zero / <input type="checkbox"/> for 12 months / <input type="checkbox"/> _____ (if not indicated order will expire one year from date signed)		
GENERAL PLAN COMMUNICATION		
Special instructions/notes:		

Ordering Provider: Initial here _____ and proceed to the next page.

ADULT REACTION MANAGEMENT

- Observe for **hypersensitivity reaction:** Fever, chills, rigors, pruritus, rash, cough, sneezing, throat irritation
- If reaction occurs:
 - Stop infusion
 - Maintain/establish vascular access
 - Notify referring provider
 - Consider giving the following PRN
 1. Acetaminophen (Tylenol) 650mg PO **OR** _____mg for pain or fever > 38 C/100.4 F
 2. Diphenhydramine (Benadryl) 25-50mg in 10ml NS slow IV push for rash, itching, pruritis
 3. Ranitidine 25mg in 10ml NS slow IV push over 5 minutes (Consider if patient already given IV Benadryl)
 4. Ondansetron (Zofran) 4mg Slow IV push over 5 minutes for nausea or vomiting.
 5. Methylprednisolone (Solumedrol) 125mg **OR** _____mg slow IV push.
 6. Other _____
 - When symptoms resolve resume infusion at 50% previous rate and increase per manufacturer’s guidelines
- Severe allergic/anaphylactic reaction:**
 - If symptoms are rapidly progressing or continuing after administration of prn medications above and signs symptoms of severe allergic/anaphylactic reaction (angioedema, swelling of the mouth, tongue, lips, or airway, dyspnea, bronchospasm with or without hypotension or hypertension.)
 1. Call 911
 2. Consider giving epinephrine (1:1000 strength) 0.3ml IM. May repeat every 5-15 minutes to a maximum of 3 doses.
 3. Treat hypotension with 500ml 0.9% sodium chloride bolus. Repeat as needed to maintain systolic BP >90.
 4. Have oxygen by nasal canula available and administer 2-15 liters, titrate to keep Spo2 >92%
 5. Have Automated External Defibrillator available
 6. Notify referring provider. If unable to reach referring provider, notify Local Medical Director.
 7. Discontinue treatment

*Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating CIMZIA and periodically during therapy. Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating CIMZIA, assess if treatment for latent tuberculosis is needed; and consider an induration of 5 mm or greater a positive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

*Test patients for HBV infection before initiating treatment with CIMZIA. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.

Patient Name

Patient Date of Birth

Provider Name (Print)

Provider Signature

Date

Designate the desired location and fax the order form to:

CALIFORNIA fax: (844) 889-0275 | ___ San Mateo ___ Fremont ___ San Ramon ___ TBD

ILLINOIS fax: (312) 253-7244 | ___ Glenview ___ Schaumburg ___ TBD

KANSAS / MISSOURI fax: (844) 900-1292 | ___ Overland Park, KS ___ Lee’s Summit, MO ___ Briarcliff, MO ___ TBD

OHIO fax: (844) 627-2675 | ___ Dublin ___ Pickerington ___ TBD

PENNSYLVANIA fax: (844) 820-9641 | ___ Malvern ___ Bensalem ___ Montgomeryville ___ East Shore ___ West Shore ___ TBD

TENNESSEE fax: (844) 627-2518 | ___ Brentwood ___ Hendersonville ___ TBD

